公开(公告)号：US5397702A

公开(公告)日：1995-03-14

申请号：US955916

申请日：1992-10-02

申请人： Michael D. Cahalan ,  Kanianthara G. Chandy ,  Stephan Grissmer ,  Sanjiu Ghanshani ,  George A. Gutman ,  Brent A. Dethlefs

发明人： Michael D. Cahalan ,  Kanianthara G. Chandy ,  Stephan Grissmer ,  Sanjiu Ghanshani ,  George A. Gutman ,  Brent A. Dethlefs

IPC分类号： A61K39/395 ,  A61K47/48 ,  G01N33/50 ,  G01N33/564 ,  C12P21/06

CPC分类号： G01N33/5008 ,  A61K39/39533 ,  A61K47/48561 ,  G01N33/564 ,  G01N2800/24

摘要： This disclosure relates to the general diagnosis and treatment of autoimmune diseases with materials identified in assays based upon the finding herein that such diseases manifest by elevated numbers of type l K.sup.+ channels in abnormal CD4.sup.- CD8.sup.- T cells.

摘要翻译： 本公开涉及通过基于本文发现的在测定中鉴定的材料的自身免疫性疾病的一般诊断和治疗，所述疾病通过异常CD4-CD8-T细胞中I型K +通道的数量增加而表现。

公开(公告)号：US5827655A

公开(公告)日：1998-10-27

申请号：US527152

申请日：1995-09-12

申请人： Kanianthara G. Chandy ,  Michael D. Cahalan ,  Stephan Grissmer ,  Alan L. Goldin ,  Brent A. Dethlefs ,  George A. Gutman ,  John J. Wasmuth

发明人： Kanianthara G. Chandy ,  Michael D. Cahalan ,  Stephan Grissmer ,  Alan L. Goldin ,  Brent A. Dethlefs ,  George A. Gutman ,  John J. Wasmuth

IPC分类号： A61K49/00 ,  C07K14/47 ,  C12N5/10 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/50 ,  G01N33/53 ,  G01N33/68 ,  C12Q1/68

CPC分类号： G01N33/6872 ,  C07K14/47 ,  G01N33/505 ,  G01N2500/10

摘要： This disclosure relates to the n K.sup.+ channel expression product of the MK3 gene or a functionally bioactive equivalent thereof and its uses, particulary in combination with identifying immune responses and materials modulating or blocking same.

摘要翻译： 本公开涉及MK3基因的+ E，不n + EE K +通道表达产物或其功能生物活性等价物及其用途，特别是与鉴定免疫应答和调节或阻断相同的材料。

公开(公告)号：US06541494B1

公开(公告)日：2003-04-01

申请号：US09479391

申请日：2000-01-06

申请人： K. George Chandy ,  Heike Wulff ,  Michael D. Cahalan ,  Stephan Grismer ,  Heiko J. Rauer ,  Mark J. Miller

发明人： K. George Chandy ,  Heike Wulff ,  Michael D. Cahalan ,  Stephan Grismer ,  Heiko J. Rauer ,  Mark J. Miller

IPC分类号： A61K31425

摘要： Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca++ activated K+ channel (IKCa1) prevents the pre-Ca++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.